Compare Stocks: ADAG, SLDB, FDMT, and AVTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.50 +9.2%	$3.26	$1.30 ▼ $4.85	$151.26M	0.54	399,467 shs	92,712 shs
AVTX Avalo Therapeutics	$12.36 +6.6%	$16.69	$11.21 ▼ $24.27	$621.57M	0.68	1.10 million shs	1.87 million shs
FDMT 4D Molecular Therapeutics	$13.10 +6.6%	$14.05	$6.96 ▼ $16.93	$678.95M	2.75	1.07 million shs	725,370 shs
SLDB Solid Biosciences	$6.40 +8.1%	$8.31	$3.79 ▼ $11.45	$634.77M	2.47	1.45 million shs	1.47 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	+11.17%	-16.42%	-30.82%	-37.77%	+30.11%
AVTX Avalo Therapeutics	+2.84%	-12.46%	-30.05%	-38.42%	-24.50%
FDMT 4D Molecular Therapeutics	+1.24%	-5.46%	-19.25%	+8.00%	+24.90%
SLDB Solid Biosciences	+7.05%	-11.77%	-33.56%	-30.02%	+0.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.50 +9.2%	$3.26	$1.30 ▼ $4.85	$151.26M	0.54	399,467 shs	92,712 shs
AVTX Avalo Therapeutics	$12.36 +6.6%	$16.69	$11.21 ▼ $24.27	$621.57M	0.68	1.10 million shs	1.87 million shs
FDMT 4D Molecular Therapeutics	$13.10 +6.6%	$14.05	$6.96 ▼ $16.93	$678.95M	2.75	1.07 million shs	725,370 shs
SLDB Solid Biosciences	$6.40 +8.1%	$8.31	$3.79 ▼ $11.45	$634.77M	2.47	1.45 million shs	1.47 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	+11.17%	-16.42%	-30.82%	-37.77%	+30.11%
AVTX Avalo Therapeutics	+2.84%	-12.46%	-30.05%	-38.42%	-24.50%
FDMT 4D Molecular Therapeutics	+1.24%	-5.46%	-19.25%	+8.00%	+24.90%
SLDB Solid Biosciences	+7.05%	-11.77%	-33.56%	-30.02%	+0.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	2.80	Moderate Buy	$8.25	230.00% Upside
AVTX Avalo Therapeutics	2.85	Moderate Buy	$45.10	264.89% Upside
FDMT 4D Molecular Therapeutics	2.75	Moderate Buy	$28.90	120.61% Upside
SLDB Solid Biosciences	2.93	Moderate Buy	$18.79	193.53% Upside

Current Analyst Ratings Breakdown

Latest ADAG, SLDB, FDMT, and AVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/19/2026	ADAG Adagene	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$7.00
10/19/2026	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$7.00
10/16/2026	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/15/2026	ADAG Adagene	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	SLDB Solid Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	SLDB Solid Biosciences	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$20.00
10/14/2026	SLDB Solid Biosciences	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/6/2026	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$26.00 ➝ $25.00
9/29/2026	FDMT 4D Molecular Therapeutics	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$29.00 ➝ $33.00
9/16/2026	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight

(Data available from 10/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$7.67M	21.53	N/A	N/A	$0.75 per share	3.33
AVTX Avalo Therapeutics	$60K	11,047.78	N/A	N/A	$4.49 per share	2.75
FDMT 4D Molecular Therapeutics	$85.21M	8.49	N/A	N/A	$8.85 per share	1.48
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$2.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$17.61M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	11/5/2026 (Estimated)
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	11/10/2026 (Estimated)
SLDB Solid Biosciences	-$174.32M	-$1.91	N/A	N/A	N/A	N/A	-71.35%	-60.58%	11/2/2026 (Estimated)

Latest ADAG, SLDB, FDMT, and AVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/10/2026	Q3 2026	FDMT 4D Molecular Therapeutics	-$1.04	N/A	N/A	N/A	$3.54 million	N/A
11/5/2026	Q3 2026	AVTX Avalo Therapeutics	-$0.5946	N/A	N/A	N/A	N/A	N/A
11/2/2026	Q3 2026	SLDB Solid Biosciences	-$0.37	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
8/6/2026	Q2 2026	SLDB Solid Biosciences	-$0.4624	-$0.38	+$0.0824	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	5.02	N/A
AVTX Avalo Therapeutics	N/A	19.31	19.31
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03
SLDB Solid Biosciences	N/A	13.82	13.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
AVTX Avalo Therapeutics	87.06%
FDMT 4D Molecular Therapeutics	99.27%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
AVTX Avalo Therapeutics	4.46%
FDMT 4D Molecular Therapeutics	7.90%
SLDB Solid Biosciences	2.66%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	128	66.05 million	52.05 million	Not Optionable
AVTX Avalo Therapeutics	33	53.63 million	51.24 million	Optionable
FDMT 4D Molecular Therapeutics	196	55.24 million	50.88 million	Optionable
SLDB Solid Biosciences	121	107.22 million	104.37 million	Optionable

ADAG, SLDB, FDMT, and AVTX Headlines

Recent News About These Companies

Solid Biosciences (NASDAQ:SLDB) Stock: Insider Gabriel Brooks Sells 4,374 Shares

October 20 at 5:07 PM | marketbeat.com

Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026

October 20 at 8:00 AM | globenewswire.com

Solid Biosciences (NASDAQ:SLDB) Shares Climb 6.6% - Should You Buy?

October 19 at 2:39 PM | marketbeat.com

Why Solid Biosciences Inc.’s (SLDB) Stock Is Up 5.06%

October 19 at 1:20 PM | aaii.comA

Solid Biosciences (NASDAQ:SLDB) Raised to "Strong-Buy" at UBS Group

October 17 at 12:35 PM | marketbeat.com

UBS initiates coverage of Solid Biosciences at buy

October 16, 2026 | msn.com

Truist Financial Initiates a Buy Rating on Solid Biosciences (SLDB)

October 15, 2026 | theglobeandmail.com

UBS Initiates Solid Biosciences at Buy With $20 Price Target

October 15, 2026 | marketscreener.comM

Solid Biosciences (NASDAQ:SLDB) Stock Falls 5.5% - Should You Sell?

October 13, 2026 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Moderate Buy" from Brokerages

October 9, 2026 | americanbankingnews.com

Solid Biosciences Inc. (NASDAQ:SLDB) Stock Has Average Target Price of $18.69 According to Brokerages

October 9, 2026 | marketbeat.com

Solid Biosciences stock fell 1.86 percent on October 2

October 5, 2026 | ad-hoc-news.deA

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 1, 2026

October 1, 2026 | biospace.comB

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2026 | globenewswire.com

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 4.7% - Here's Why

September 29, 2026 | marketbeat.com

Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations

September 25, 2026 | seekingalpha.com

Solid Biosciences (NASDAQ:SLDB) Trading Down 10% - Time to Sell?

September 23, 2026 | marketbeat.com

RBC Capital initiates coverage of Solid Biosciences at outperform

September 17, 2026 | msn.com

Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says

September 16, 2026 | finance.yahoo.com

Solid Biosciences wins new Outperform at RBC on DMD opportunity

September 16, 2026 | seekingalpha.com

Solid Biosciences (SLDB) Gets a Buy from Citi

September 12, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, SLDB, FDMT, and AVTX Company Descriptions

Adagene NASDAQ:ADAG

$2.50 +0.21 (+9.17%)

Closing price 04:00 PM Eastern

Extended Trading

$2.49 -0.01 (-0.40%)

As of 05:38 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Avalo Therapeutics NASDAQ:AVTX

$12.36 +0.77 (+6.64%)

Closing price 04:00 PM Eastern

Extended Trading

$12.36 0.00 (0.00%)

As of 05:00 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

4D Molecular Therapeutics NASDAQ:FDMT

$13.10 +0.81 (+6.59%)

Closing price 04:00 PM Eastern

Extended Trading

$13.10 +0.01 (+0.04%)

As of 05:00 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Solid Biosciences NASDAQ:SLDB

$6.40 +0.48 (+8.11%)

Closing price 04:00 PM Eastern

Extended Trading

$6.58 +0.18 (+2.80%)

As of 07:02 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADAG, SLDB, FDMT, and AVTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADAG, SLDB, FDMT, and AVTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADAG, SLDB, FDMT, and AVTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, SLDB, FDMT, and AVTX Company Descriptions

Adagene NASDAQ:ADAG

Avalo Therapeutics NASDAQ:AVTX

4D Molecular Therapeutics NASDAQ:FDMT

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADAG, SLDB, FDMT, and AVTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADAG, SLDB, FDMT, and AVTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADAG, SLDB, FDMT, and AVTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, SLDB, FDMT, and AVTX Company Descriptions

Adagene NASDAQ:ADAG

Avalo Therapeutics NASDAQ:AVTX

4D Molecular Therapeutics NASDAQ:FDMT

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools